In the News
Why do we search patents? Historically, the primary-use case was to find prior art for a potential patent application or existing patent. The patent world was effectively self-contained, with inventors and specialist searchers manually scanning for patents related to their idea.
Today’s pace of innovation and competitive intensity demand greater protection of new ideas and inventions. Yet intellectual property (IP) management is not a high business priority for many companies. Organizations that fail to recognize IP as a strategic asset put their competitive advantage and profit margins at risk. Companies can circumvent these potentially adverse impacts by maximizing the value of their creativity. Prioritizing and protecting IP assets helps organizations stay in front of competitors and drive greater growth.
IBM (NYSE:IBM) of Armonk, NY, is a technology development and consulting giant as well as a patenting powerhouse which is often featured in our Companies We Follow series here on IPWatchdog. The corporation is a major player in the big data sector and a recent big data market share report, produced by business technology practitioner community Wikibon, shows IBM with 9.3 percent, or just over $2.1 billion, of the total big data market, well in front of second-place SAP SE (NYSE:SAP) which took in $890 million, or 3.9 percent of the global big data market, in 2015. IBM CEO Ginni Rometty has reportedly stated that the company sees cognitive computing and machine learning, both of which have heavy ties to big data, growing as a market by $2 trillion over the next decade.
Decades of research and billions of dollars have poured into developing artificial intelligence, which has crossed over from science fiction to gameshow novelty to the cusp of widespread business applications.
The Trans-Pacific Partnership (TPP) is a recently ratified and controversial free trade agreement between 12 Pacific Rim countries: Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore, United States, and Vietnam. One of the more controversial provisions of the TPP concerns the data-exclusivity term for biologics, which effectively enforces a monopoly for that medication by preventing a competitive manufacturer from leveraging the owner’s data about treatment efficacy during the exclusivity term. This exclusivity term runs concurrently with any patent protection and can extend beyond the expiration of applicable patents.